Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to 52.36%.

  • Karyopharm Therapeutics' EBITDA Margin rose 500600.0% to 52.36% in Q4 2025 from the same period last year, while for Dec 2025 it was 62.1%, marking a year-over-year increase of 201400.0%. This contributed to the annual value of 62.1% for FY2025, which is 201400.0% up from last year.
  • Per Karyopharm Therapeutics' latest filing, its EBITDA Margin stood at 52.36% for Q4 2025, which was up 500600.0% from 34.56% recorded in Q3 2025.
  • Karyopharm Therapeutics' 5-year EBITDA Margin high stood at 37.19% for Q4 2021, and its period low was 225.16% during Q1 2021.
  • In the last 5 years, Karyopharm Therapeutics' EBITDA Margin had a median value of 86.07% in 2022 and averaged 92.27%.
  • Within the past 5 years, the most significant YoY rise in Karyopharm Therapeutics' EBITDA Margin was 1526100bps (2022), while the steepest drop was -1380500bps (2022).
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' EBITDA Margin stood at 37.19% in 2021, then plummeted by -371bps to 100.86% in 2022, then fell by -11bps to 112.03% in 2023, then rose by 9bps to 102.42% in 2024, then soared by 49bps to 52.36% in 2025.
  • Its EBITDA Margin was 52.36% in Q4 2025, compared to 34.56% in Q3 2025 and 64.3% in Q2 2025.